Hawkeye Bio Granted U.S. Patent for Graphene Biosensor Platform Enabling Ultra-Sensitive Protease Biomarker Detection
Patent covers pristine graphene–based biosensor technology to translate protease activity into measurable optical signals for early cancer detection
Hawkeye Bio selected as an awardee in the Innovations for Vets QuickFire Challenge Presented by Johnson & Johnson Innovation and the Johnson & Johnson Office of Military and Veterans Affairs
Hawkeye Bio is selected by Johnson & Johnson Innovation, together with Johnson & Johnson Office of Military and Veterans Affairs, as an awardee in the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma. Three companies were selected in each application area; Hawkeye is focused on deploying its LEAP blood test for the early detection of lung cancer throughout the VA community.